title: Imatinib mesylate causes growth plate closure in vivo.
authors.forename: K
authors.initials: K
authors.lastname: Vandyke
authors.forename: A L
authors.initials: AL
authors.lastname: Dewar
authors.forename: S
authors.initials: S
authors.lastname: Fitter
authors.forename: D
authors.initials: D
authors.lastname: Menicanin
authors.forename: L B
authors.initials: LB
authors.lastname: To
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
authors.forename: A C W
authors.initials: AC
authors.lastname: Zannettino
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D001549:Benzamides; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000139:chemically induced*; D006132:Growth Plate / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects* / Q000494:pharmacology; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate